These CHO-M libraries boost expression over broad range of difficult-to-express proteins.
Geneva, Switzerland (PRWEB) March 26, 2014
Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s chief scientific officer, Pierre-Allain Girod, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for MAb Expression Bottlenecks,” as part of the molecular biology session on Tuesday, April 1, 2014 at the 18th Annual Human Antibodies and Hybridomas Conference being held March 31 – April 2 in Vienna, Austria.
Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for MAb Expression Bottlenecks
As an alternative to extensive cell clone screening that requires significant resources and infrastructure, Selexis pursued a host cell engineering approach to address expression issues in CHO cells. To identify auxiliary (chaperone) proteins essential for high-level recombinant protein production, we leveraged data from our completed CHO-M Genome and Transcriptome project and designed a collection of CHO-M libraries expressing complex pools of auxiliary (chaperone) proteins in a single screen. Each CHO-Mplus library expresses a diversity of auxiliary proteins involved in specific secretory pathways and cellular metabolism. This type of approach provides an overall understanding of the pathways controlling secretion of a defined recombinant protein in a single screen, rather than addressing these issues on a chaperone-by-chaperone basis. These CHO-M libraries boost expression over broad range of difficult-to-express proteins.
For more information and registration, please visit the Human Antibodies and Hybridomas 2014 Conference website at http://www.meetingsmanagement.com/hah_2014
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information: